First experience with the Hugo™ robot-assisted surgery system for endometriosis: A descriptive study

Area of Science:

• Minimally Invasive Surgery
• Gynecological Oncology
• Surgical Technology

Background:

• The Medtronic Hugo™ Robot-assisted Surgery (RAS) system is a new platform recently approved for clinical use.
• Endometriosis surgery presents unique challenges requiring advanced surgical techniques.
• Evaluating novel RAS systems is crucial for advancing gynecological surgical care.

Purpose of the Study:

• To assess the safety and feasibility of the Medtronic Hugo™ RAS system in endometriosis surgery.
• To determine the primary outcome of safe case completion without major complications (Clavien-Dindo grade ≤2) or conversion.
• To evaluate peri- and postoperative outcomes including complications and readmission rates.

Main Methods:

• A descriptive study using the IDEAL framework 1/2a for surgical innovation.
• Included surgeries for endometriosis performed on the Medtronic Hugo™ RAS system.
• Data collected included patient demographics, operative details, complications, and 30-day readmission rates.

Main Results:

• Twelve patients underwent endometriosis surgery using the Medtronic Hugo™ RAS system.
• All cases were completed successfully without intraoperative complications or conversion to open surgery.
• Four patients experienced minor postoperative complications (Clavien-Dindo grade 1); no 30-day readmissions occurred.

Conclusions:

• The Medtronic Hugo™ RAS system demonstrated safety and feasibility for robot-assisted endometriosis surgery in this pilot study.
• The system's performance metrics (docking, console times, blood loss, hospital stay) were comparable to existing literature.
• The introduction of new RAS systems like Hugo™ is vital for technological advancement in surgical care globally.